Two Cases of Basal Cell Carcinoma Treated with Recombinant Alpha-2 Interferon

Two patients with basal cell carcinoma (BCC) were treated with recombinant alpha-2 interferon. One patient was a 48-year-old man who had a 8 × 5 an sized ulcer with an elevated border on the face for 10 years, which revealed BCC of the solid type, histopathologically. He received intralesional injections of recombinant alpha-2 interferon (total dose: 51 × 10⁶ IU) for 11 weeks. The biopsy specimen after completion of injections showed a remaining small tumor cell nest in the lesion despite clinical remission.

The other patient was a 75-year-old female, who had 1.2 × 1.2 cm-sized, darkly pigmented, nodular BCC of the solid type on the nose for 3 years. She also received intralesional injections of recombinant alpha-2 interferon (total dose: 18 × 10⁶ IU) for 8 weeks. The biopsy specimen after completion of injections did not show any tumor cells.